Neurocritical Care News

Transcranial static magnetic stimulation did not significantly modify ALS disease progression at 6 months compared with sham, but long-term follow up showed an increase in tracheostomy-free survival, data show.

The first patient has been dosed in a phase 3 clinical trial of oral cladribine for the treatment of generalized myasthenia gravis, according to the manufacturer.

Treatment-limiting decisions were made for almost half of patients with severe traumatic brain injuries, with higher rates in those older in age, according to data.

The FDA has granted fast-track designation to an investigational tau positron emission tomography diagnostic that can be used for a range of neurodegenerative conditions, according to the manufacturer.

Deep brain stimulation (DBS) therapy has been a safe and effective treatment option for Parkinson’s disease for more than 30 years, but another surgical option for the therapy has emerged.

For infants with Down syndrome, early intervention to address obstructive sleep apnea may lead to better cognitive and behavioral outcomes at 36 months, according to new research from The Lancet.

An Alabama-based company announced that the FDA has granted 510(k) clearance to its cyber device and AI system, which are designed to improve efficiency and accuracy of glioblastoma care.

A Maryland-based neurotechnology company has secured a U.S. patent for its novel prosthetic translucent, cranial implant intended for use during neurosurgical procedures.

The FDA has granted 510(k) clearance to a plant-based, hemostatic gel to treat moderate to severe bleeding, according to the manufacturer.

The FDA has granted rare pediatric disease designation to an investigational oligonucleotide for the treatment of boys with Duchenne muscular dystrophy who are amenable to exon 53 skipping, according to the manufacturer.